[
  {
    "ts": null,
    "headline": "21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity",
    "summary": "CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity",
    "url": "https://finnhub.io/api/news?id=0ad2e92c40632fbf0a4d0550ea11ff0cc4ddb1c12d7fa2e21b1aebc634b6789e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750259280,
      "headline": "21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity",
      "id": 135361263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity",
      "url": "https://finnhub.io/api/news?id=0ad2e92c40632fbf0a4d0550ea11ff0cc4ddb1c12d7fa2e21b1aebc634b6789e"
    }
  },
  {
    "ts": null,
    "headline": "H.C. Wainwright sees potential competition for Sage from Biogen",
    "summary": "H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b",
    "url": "https://finnhub.io/api/news?id=7181103317f95e019e4fb5b35d7040ff84952b6684810f7dccc685786f680136",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750254313,
      "headline": "H.C. Wainwright sees potential competition for Sage from Biogen",
      "id": 135361265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b",
      "url": "https://finnhub.io/api/news?id=7181103317f95e019e4fb5b35d7040ff84952b6684810f7dccc685786f680136"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
    "summary": "Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWS",
    "url": "https://finnhub.io/api/news?id=a9180bd7d02f1c9c1fe8855714656f55e8a8d290868a380c3c9dc77b1745b62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750246200,
      "headline": "Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
      "id": 135361269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWS",
      "url": "https://finnhub.io/api/news?id=a9180bd7d02f1c9c1fe8855714656f55e8a8d290868a380c3c9dc77b1745b62f"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
    "summary": "Biogen Inc. announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich...",
    "url": "https://finnhub.io/api/news?id=f390a8c5e439f2b9784a6dd23eed484e40011aa2b11d99e329f717a4a50a3b80",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750242053,
      "headline": "Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
      "id": 135357354,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich...",
      "url": "https://finnhub.io/api/news?id=f390a8c5e439f2b9784a6dd23eed484e40011aa2b11d99e329f717a4a50a3b80"
    }
  }
]